Y. Ralph Chu

Y. Ralph Chu, M.D. is the CEO and Chief Medical Officer of the Chu Vision Institute and Chu Surgery Center in Minnesota. Dr. Chu earned his medical degree from Northwestern University in Chicago where he was a member of the Alpha Omega Alpha Honor Society. He completed his internship at Evanston Hospital, followed by a residency in ophthalmology at Duke University Eye Center. He furthered his medical training with a one-year fellowship in Minneapolis where he specialized in cornea and external disease, refractive, glaucoma, cataract, and lens implant surgery.

Dr. Chu is an internationally recognized leader, innovator, and pioneer of new technologies in cataract and refractive surgery and has been involved in over 95 clinical trials across various ophthalmic diseases. He has published over 100 national meeting presentations, abstracts, and scientific papers. Dr. Chu has also been a member of several product launch committees for refractive surgery products. Dr. Chu is a clinical investigator in Ocuphire's MIRA-3 Phase 3 clinical trial evaluating the safety and efficacy of Nyxol for reversal of mydriasis.